Nektar Therapeutics (NKTR)
37.27
+0.02
(+0.05%)
USD |
NASDAQ |
Nov 13, 16:00
37.17
-0.10
(-0.27%)
Pre-Market: 19:59
Nektar Therapeutics Enterprise Value : 789.44M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 789.44M |
| November 12, 2026 | 788.76M |
| November 11, 2026 | 829.47M |
| November 10, 2026 | 806.89M |
| November 09, 2026 | 808.43M |
| November 06, 2026 | 789.10M |
| November 05, 2026 | 751.13M |
| November 04, 2026 | 830.84M |
| November 03, 2026 | 806.21M |
| November 02, 2026 | 778.50M |
| October 30, 2026 | 844.19M |
| October 29, 2026 | 854.79M |
| October 28, 2026 | 833.24M |
| October 27, 2026 | 813.39M |
| October 26, 2026 | 795.60M |
| October 23, 2026 | 787.73M |
| October 22, 2026 | 836.66M |
| October 21, 2026 | 823.66M |
| October 20, 2026 | 856.16M |
| October 19, 2026 | 767.89M |
| October 16, 2026 | 738.47M |
| October 15, 2026 | 804.84M |
| October 14, 2026 | 776.44M |
| October 13, 2026 | 811.68M |
| October 12, 2026 | 877.37M |
| Date | Value |
|---|---|
| October 09, 2026 | 922.88M |
| October 08, 2026 | 910.22M |
| October 07, 2026 | 891.74M |
| October 06, 2026 | 879.77M |
| October 05, 2026 | 958.80M |
| October 02, 2026 | 1.005B |
| October 01, 2026 | 1.122B |
| September 30, 2026 | 1.586B |
| September 29, 2026 | 1.473B |
| September 28, 2026 | 1.513B |
| September 25, 2026 | 1.399B |
| September 24, 2026 | 1.478B |
| September 23, 2026 | 1.420B |
| September 22, 2026 | 1.532B |
| September 21, 2026 | 1.733B |
| September 18, 2026 | 1.742B |
| September 17, 2026 | 1.785B |
| September 16, 2026 | 1.751B |
| September 15, 2026 | 1.726B |
| September 14, 2026 | 1.789B |
| September 11, 2026 | 1.832B |
| September 10, 2026 | 1.863B |
| September 09, 2026 | 1.954B |
| September 08, 2026 | 2.026B |
| September 04, 2026 | 1.984B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.403T |
| Arrowhead Pharmaceuticals, Inc. | 6.959B |
| Inovio Pharmaceuticals, Inc. | 116.48M |
| Ionis Pharmaceuticals, Inc. | 5.125B |
| Fortress Biotech, Inc. | -33.25M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -55.65M |
| Revenue (Quarterly) | 9.386M |
| Total Expenses (Quarterly) | 65.04M |
| EPS Diluted (Quarterly) | -1.628 |
| Gross Profit Margin (Quarterly) | 98.20% |
| Profit Margin (Quarterly) | -592.9% |
| Earnings Yield | -17.31% |
| Normalized Earnings Yield | -16.50 |